Daehwa Pharmaceutical signs Chinese technology transfer agreement of ‘Liporaxel Soln’ for USD 25 million

Published: 2017-09-11 14:41:34

Updated: 2017-09-11 14:41:34

Daehwa Pharmaceutical announced on the 6^th that the company signed a technology transfer agreement of the world’s first approved oral paclitaxel anticancer drug(Korean product name: Liporaxel Soln) for USD 25 million and other royalties with Chinese RMX Biopharma.

The total technology licensing fees for the technology transfer agreement are about USD 25 million; after paying an upfront payment...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.